文献速递咽喉与嗓音睡眠呼吸障碍小儿耳鼻咽喉

黏多糖贮积症的气道疾病负担:跨亚型证据

The Burden of Airway Disease in Mucopolysaccharidoses: Evidence Across Subtypes.
PubMed 文献 · Laryngoscope · 2026-08-28

本范围综述纳入65项病例系列(3715例,4级证据),汇总黏多糖贮积症各亚型的气道表现。上气道软组织肥大、巨舌、喉气管受累及阻塞性睡眠呼吸暂停普遍存在,气管切开率7.0%,呼吸相关死亡占10.4%。结论强调早期、系统、纵向气道评估的重要性。

要点

  • 腺样体肥大52.5%(MPS IV)至78.5%(MPS I),扁桃体肥大38.5%(MPS I)至59.5%(MPS II)。
  • 阻塞性睡眠呼吸暂停高发:MPS I 61.7%、MPS II 75.3%、MPS VI 83.7%。
  • 气管狭窄在MPS II达92.3%、MPS IV达85.4%,气管切开率7.0%。

核心结论

  • 黏多糖贮积症的气道疾病常见、多平面且具有临床后果,阻塞性睡眠呼吸暂停和进行性喉气管病变负担显著。
  • 早期、系统、纵向气道评估对指导各亚型的咨询和管理至关重要。

研究设计与样本

  • 遵循PRISMA-ScR的范围综述,检索PubMed、CINAHL、Ovid Embase、Ovid MEDLINE和Ovid All EBM Reviews。
  • 纳入截至2026年6月、报告≥5例患者气道表现的英文和法文研究,共65项病例系列(3715例,4级证据)。
  • 采用比例Meta分析估计合并患病率及95%置信区间(CI)。

主要发现

  • 腺样体肥大患病率从52.5%(MPS IV;95% CI,21.0-82.1)到78.5%(MPS I;95% CI,23.9-97.7)。
  • 扁桃体肥大患病率从38.5%(MPS I;95% CI,17.5-64.9)到59.5%(MPS II;95% CI,34.6-80.4)。
  • 巨舌症常见,MPS II患病率最高(79.7%;95% CI,16.5-98.7)。
  • 气管狭窄在MPS II达92.3%(95% CI,7.0-99.9),在MPS IV达85.4%(95% CI,38.3-98.2)。
  • 阻塞性睡眠呼吸暂停患病率:MPS I 61.7%(95% CI,45.3-75.9)、MPS II 75.3%(95% CI,43.1-92.4)、MPS VI 83.7%(95% CI,48.0-96.6)。

临床怎么用

  • 对黏多糖贮积症患者应早期开展系统、纵向气道评估,包括上气道软组织、喉气管及睡眠呼吸监测。
  • 根据亚型特异性气道表现模式(如MPS II的巨舌和气管狭窄、MPS VI的高阻塞性睡眠呼吸暂停患病率)进行个体化咨询和管理。

局限性

  • 纳入研究均为4级证据的病例系列,证据等级较低。
  • 部分合并患病率的95%置信区间较宽,提示异质性或样本量有限。
  • 仅纳入英文和法文研究,可能存在语言偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To synthesize the prevalence and subtype-specific patterns of airway manifestations in mucopolysaccharidoses (MPS) and summarize related morbidity and mortality. DATA SOURCES: PubMed, CINAHL, Ovid Embase, Ovid MEDLINE, and Ovid All EBM Reviews. REVIEW METHODS: PRISMA-ScR guided scoping review of English and French-language studies reporting airway manifestations in ≥ 5 patients up to June 2026. Pooled prevalences with 95% confidence intervals (CI) were estimated using proportional meta-analysis. RESULTS: Of 2359 records, 65 case series (3715 participants; Level 4 evidence) were included. Upper-airway soft tissue hypertrophy was common: adenoid hypertrophy ranged from 52.5% (MPS IV; 95% CI, 21.0-82.1) to 78.5% (MPS I; 95% CI, 23.9-97.7); tonsillar hypertrophy ranged from 38.5% (MPS I; 95% CI, 17.5-64.9) to 59.5% (MPS II; 95% CI, 34.6-80.4). Macroglossia was frequent, with the highest prevalence in MPS II (79.7%; 95% CI, 16.5-98.7). Laryngotracheal involvement varied, with tracheal narrowing reaching 92.3% (95% CI, 7.0-99.9) in MPS II and 85.4% (95% CI, 38.3-98.2) in MPS IV. Obstructive sleep apnea was highly prevalent across subtypes (MPS I, 61.7%; 95% CI, 45.3-75.9; MPS II, 75.3%; 95% CI, 43.1-92.4; MPS VI, 83.7%; 95% CI, 48.0-96.6). Tracheotomy was required in 7.0% (95% CI, 4.9-9.9), and respiratory-related deaths occurred in 10.4% (95% CI, 5.2-19.9) of patients with available data. CONCLUSION: Airway disease in MPS is common, multilevel, and clinically consequential, with substantial burdens of OSA and progressive laryngotracheal pathology. Early, systematic, longitudinal airway assessment is essential to guide counseling and management across MPS subtypes.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Edward J, Pincivy A, Bergeron M, et al. The Burden of Airway Disease in Mucopolysaccharidoses: Evidence Across Subtypes. Laryngoscope. 2026. PMID: 42665430. doi:10.1002/lary.70868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。